Nuvectis Pharma (NVCT) Net Income towards Common Stockholders (2021 - 2026)
Nuvectis Pharma (NVCT) reported Net Income towards Common Stockholders of -$6.0 million for Q1 2026, down 13.47% on a YoY basis from -$7.0 million in Q1 2025, and up 17.28% sequentially from -$7.3 million in Q4 2025.
Nuvectis Pharma (NVCT) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Nuvectis Pharma (NVCT) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$6.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 13.47% year-over-year to -$6.0 million; the trailing twelve-month figure through Mar 2026 stood at -$29.6 million (down 46.76% YoY), and the FY2025 full-year result was -$28.9 million, down 51.95% from the prior year.
- Net Income towards Common Stockholders improved to -$6.0 million in Q1 2026, from -$7.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.9 million in Q1 2022 to a low of -$9.9 million in Q3 2025.
- A 5-year average of -$5.6 million and a median of -$5.9 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Peak annual rise in Net Income towards Common Stockholders reached 39.9% in 2022, while the deepest fall reached 196.15% in 2022.
- Tracing NVCT's Net Income towards Common Stockholders over 5 years: stood at -$6.7 million in 2022, then rose by 1.11% to -$6.6 million in 2023, then climbed by 5.65% to -$6.2 million in 2024, then retreated by 17.06% to -$7.3 million in 2025, then grew by 17.28% to -$6.0 million in 2026.
- Business Quant data shows NVCT's Net Income towards Common Stockholders at -$6.0 million in Q1 2026, -$7.3 million in Q4 2025, and -$9.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Nuvectis Pharma | 453.54 Mn | 453.54 Mn | - | -6.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.05 Mn |
| Dec 31, 2025 | -7.31 Mn |
| Sep 30, 2025 | -9.89 Mn |
| Jun 30, 2025 | -6.33 Mn |
| Mar 31, 2025 | -5.33 Mn |
| Dec 31, 2024 | -6.25 Mn |
| Sep 30, 2024 | -4.15 Mn |
| Jun 30, 2024 | -4.43 Mn |
| Mar 31, 2024 | -4.17 Mn |
| Dec 31, 2023 | -6.62 Mn |
| Sep 30, 2023 | -5.88 Mn |
| Jun 30, 2023 | -5.71 Mn |
| Mar 31, 2023 | -4.05 Mn |
| Dec 31, 2022 | -6.70 Mn |
| Sep 30, 2022 | -5.88 Mn |
| Jun 30, 2022 | -3.57 Mn |
| Mar 31, 2022 | -2.94 Mn |
| Dec 31, 2021 | -2.26 Mn |
| Sep 30, 2021 | -4.67 Mn |
| Jun 30, 2021 | -5.94 Mn |